These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 11772281)

  • 1. The place of pegvisomant in the management of acromegaly.
    Parkinson C; Trainer PJ
    Expert Opin Investig Drugs; 2001 Sep; 10(9):1725-35. PubMed ID: 11772281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegvisomant: an advance in clinical efficacy in acromegaly.
    Stewart PM
    Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S27-32. PubMed ID: 12670298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegvisomant in the treatment of acromegaly.
    Parkinson C; Scarlett JA; Trainer PJ
    Adv Drug Deliv Rev; 2003 Sep; 55(10):1303-14. PubMed ID: 14499709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with pegvisomant in the treatment of acromegaly.
    Drake WM
    Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The place of pegvisomant in the acromegaly treatment algorithm.
    Paisley AN; Trainer PJ; Drake WM
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
    Tritos NA; Biller BM
    Pituitary; 2017 Feb; 20(1):129-135. PubMed ID: 27631335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.
    Paisley AN; Trainer P; Drake W
    Expert Opin Biol Ther; 2004 Mar; 4(3):421-5. PubMed ID: 15006735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy.
    Frohman LA; Bonert V
    Pituitary; 2007; 10(3):283-9. PubMed ID: 17534717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
    Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
    N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist.
    Drake WM; Parkinson C; Akker SA; Monson JP; Besser GM; Trainer PJ
    Eur J Endocrinol; 2001 Oct; 145(4):451-6. PubMed ID: 11581004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
    Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
    Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
    Ezzat S; Gaspo R; Serri O; Ur E; Chik CL
    Clin Invest Med; 2009 Dec; 32(6):E265. PubMed ID: 20003832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.
    Parkinson C; Trainer PJ
    Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S119-23. PubMed ID: 10984267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
    Parkinson C; Whatmore AJ; Yates AP; Drake WM; Brabant G; Clayton PE; Trainer PJ
    Clin Endocrinol (Oxf); 2003 Aug; 59(2):168-74. PubMed ID: 12864793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical treatment in acromegaly.
    Paisley AN; Trainer PJ
    Curr Opin Pharmacol; 2003 Dec; 3(6):672-7. PubMed ID: 14644022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].
    Zgliczyński W; Zdunowski P
    Endokrynol Pol; 2007; 58(5):408-16. PubMed ID: 18058736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of pegvisomant in the treatment of acromegaly.
    Roelfsema F; Biermasz NR; Pereira AM; Romijn JA
    Expert Opin Biol Ther; 2008 May; 8(5):691-704. PubMed ID: 18407771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.